Watch NEUP. Know when insiders buy.
One email the day a filing lands. Free.
NEUP
Neuphoria Therapeutics Inc.
3.68
−0.03 −0.81%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $19.9MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$13.5MNET CASH —52W 3.30 – 20.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2026 · Jun 30derived | — | — | — | −$5.5M | −$4.9M | — | -0.95 | $1.2M | — | — | Sep 18 |
| Q3 2026 · Mar 31 | — | — | — | −$1.2M | −$505K | −104.5% | -0.09 | −$3.3M | — | — | May 15 |
| Q2 2026 · Dec 31 | — | — | — | −$4.1M | $1.9M | — | -0.77 | −$6.4M | — | — | May 15 |
| Q1 2026 · Sep 30 | — | — | — | −$5.7M | −$9.9M | — | -4.41 | −$3.8M | — | — | May 15 |
| Q4 2025 · Jun 30derived | −$13K | — | — | −$5.8M | −$8.9M | — | -5.79 | −$3.6M | — | — | Sep 18 |
| Q3 2025 · Mar 31 | $15M | — | — | $12M | $11.3M | — | 6.55 | $11.5M | — | — | May 15 |
| Q2 2025 · Dec 31 | $663K | — | — | −$3.7M | −$1.9M | — | -1.79 | −$3.4M | — | — | May 15 |
| Q1 2025 · Sep 30 | — | — | — | −$3.6M | −$805K | — | -0.62 | −$4.4M | — | — | May 15 |
| Q4 2024 · Jun 30derived | — | — | — | −$5.5M | −$2.7M | — | -3.42 | −$3M | — | — | Sep 29 |
| Q3 2024 · Mar 31 | — | — | — | −$2.4M | −$2.8M | — | -2.83 | −$3.3M | — | — | May 20 |
| Q2 2024 · Dec 31 | — | — | — | −$4.6M | −$4.6M | — | -5.31 | −$3.9M | — | — | May 20 |
| Q1 2024 · Sep 30 | — | — | — | −$5.5M | −$5.5M | — | 0.00 | −$4.4M | — | — | May 20 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Jun 30 | $1.2M | — | −$16.5M | −$13.5M | -1145.7% | -3.06 | −$12.4M | — | — | — | — |
| FY2025 · to Jun 30 | $15.6M | — | −$1.1M | −$370K | -2.4% | -0.23 | $77K | — | — | — | — |
| FY2024 · to Jun 30 | — | — | −$17.9M | −$15.5M | — | -18.62 | −$14.7M | — | — | — | — |
| FY2023 · to Jun 30 | — | — | −$22M | −$21.4M | — | -0.02 | −$14.6M | — | — | — | — |
Every number comes from Neuphoria Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.